Disease overview The myelodysplastic syndromes (MDS) are a very heterogeneous group
of myeloid disorders characterized by peripheral blood cytopenias and increased risk of …

The heterogeneous nature of myelodysplastic syndromes (MDS) demands a complex and
personalized variety of therapeutic approaches. Among them, allogeneic hematopoietic …

Background Patients with anemia and lower-risk myelodysplastic syndromes in whom
erythropoiesis-stimulating agent therapy is not effective generally become dependent on red …

Background Myelodysplastic syndromes are characterised by ineffective erythropoiesis.
Luspatercept (ACE-536) is a novel fusion protein that blocks transforming growth factor beta …

The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid
disorders with a highly variable disease course. Diagnostic criteria to better stratify patients …

Myelodysplastic syndromes (MDS) represent a heterogeneous group of myeloid neoplasms
that are characterized by ineffective hematopoiesis, variable cytopenias, and a risk of …

Disease overview The myelodysplastic syndromes (MDS) are a very heterogeneous group
of myeloid disorders characterized by peripheral blood cytopenias and increased risk of …

PURPOSE Patients with lower-risk (LR) myelodysplastic syndromes (MDS) who are RBC
transfusion dependent and have experienced relapse after or are refractory to erythropoiesis …

Purpose Azacitidine is standard, first-line therapy in higher-risk myelodysplastic syndromes
(MDS). Whether azacitidine-based combinations with lenalidomide or vorinostat produce …

Myelodysplastic syndromes (MDS) consist of a heterogeneous group of myeloid neoplasms
characterized by inefficient hematopoiesis, variable cytopenias and a considerable risk of …